Research programme: thiazolide antiviral therapeutics - Romark Laboratories

Drug Profile

Research programme: thiazolide antiviral therapeutics - Romark Laboratories

Alternative Names: RM-4864; RM-4865; RM-5038; RM-5061; RM-5064; RM-6427

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Romark Laboratories
  • Developer Romark Laboratories; Stanford University
  • Class Small molecules; Thiazoles
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Viral infections
  • No development reported Hepatitis B
  • Discontinued Hepatitis C; Hepatitis D; Herpes simplex virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)
  • 13 Oct 2015 Discontinued for Herpes simplex virus infections in USA (PO)
  • 13 Oct 2015 Discontinued for Respiratory syncytial virus infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top